ITI-1284
Sponsors
Intra-Cellular Therapies Inc., Intra-Cellular Therapies, Inc.
Conditions
Agitation Associated With Alzheimer's DementiaAgitation Associated with Alzheimer’s DementiaAlzheimer DiseaseGeneralized Anxiety DisorderPsychosis associated with Alzheimer’s DiseasePsychotic Disorders
Phase 2
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
RecruitingNCT06540833
Start: 2024-08-15End: 2028-12-29Target: 370Updated: 2026-08-31
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
RecruitingNCT06651567
Start: 2024-10-22End: 2027-12-28Target: 320Updated: 2026-08-26
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients with Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment
RecruitingCTIS2024-513302-56-00
Start: 2025-11-17Target: 312Updated: 2025-12-17
A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Efficacy, Safety, and Tolerability of ITI1284 in Patients with Psychosis Associated with Alzheimer’s Disease
RecruitingCTIS2024-513035-25-00
Start: 2025-07-11Target: 216Updated: 2026-01-21
A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study of the Efficacy, Safety, and Tolerability of ITI-1284 in Patients with Agitation Associated with Alzheimer’s Dementia
RecruitingCTIS2024-514680-26-00
Start: 2025-07-17Target: 137Updated: 2025-10-23
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as Monotherapy Treatment in Patients with Generalized Anxiety Disorder Who Have Had Inadequate Response to Generalized Anxiety Disorder Treatment
RecruitingCTIS2024-516684-82-00
Start: 2025-07-21Target: 349Updated: 2025-11-19